Risultati per: Cellule killer naturali modificate per combattere i tumori

I tempi da fine cure in un decreto, le tabelle per 9 neoplasie

Marchetti, possibili cure mirate con la medicina di precisione

‘Scarsa adesione per varie neoplasie, la prevenzione salva la vita’

Al Sant’Orsola di Bologna su un paziente di 75 anni

Al Sant’Orsola di Bologna su un paziente di 75 anni

Per tumori in stadio 1 per la guarigione basta un anno. Favo, possibili tempi più brevi per l’oblio oncologico

208mila diagnosi maschili l’anno. Il 17 consulti medici a bordo ed un vademecum. Cesare Bocci testimonial

Studio Usa, +17% di rischio nei nati tra 1965-69. Di Maio, faro sugli stili di vita

In studi fase 1. A Roma ricercatori dal mondo per nuove ricerche

Sarà sfruttata la sensoristica all’avanguardia insieme all’intelligenza artificiale.

Da maggio, è dedicata alla raccolta del 5 per mille

Studio dell’Università di Trento pubblicato su ‘Science Advances

Background
Colorectal cancer (CRC) is the second most frequently diagnosed cancer and the fifth leading cause of cancer-related death in China. However, resistance to multiple chemotherapeutics after surgery leads to failure of the main therapy to CRC. Natural killer (NK) cells are innate cytotoxic lymphocytes that exhibit strong cytotoxic activity against tumour cells. NK cell-based therapy, either alone or in combination with chemotherapy, has achieved favourable results and holds promise for addressing recurrence and metastasis in CRC patients after surgery.

Methods and analysis
This is a prospective, randomised controlled clinical trial to evaluate efficacy and safety of interleukin 2 activated NK cells injection combined with XELOX (capecitabine plus oxaliplatin)-based chemotherapy for postoperative CRC patients. Participants will be randomly divided into treatment group and control group, and every group includes 40 patients. The treatment group will also receive NK cells (5×109) with+XELOX-based chemotherapy, while the control group will receive only XELOX-based chemotherapy. This treatment will be repeated for eight cycles (6 months). The follow-up period lasts about 3 years, during which CEA, CA19-9, CA125, enhancement CT and colonoscopy will be conducted. The primary endpoints of this study are progression-free survival and overall survival, while the secondary endpoint is safety (number and severity of adverse events). Additionally, we aim to identify cancer stem cells in peripheral blood and predictive biomarkers (cytokines secreted by NK cells and activated markers of NK cells) that indicate patients who achieve an effective response.

Ethics and dissemination
The study has been approved by the Clinical Research Ethics Committee of our hospital (approval number 2023LLSC006) and the Chinese Clinical Trials. It will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all participants. The study findings will be submitted to peer-reviewed journals for publication.

Trial registration number
Chinese Clinical Trials Registry (ChiCTR2300075861).

Di Maio (Aiom), ‘pesante ma riduce i rischi di recidive’